86.04 -0.04 (-0.05%)
After hours: 4:05PM EDT
|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||85.88 - 86.31|
|52 Week Range||66.93 - 86.90|
|PE Ratio (TTM)||31.41|
|Forward Dividend & Yield||2.72 (3.16%)|
|1y Target Est||88.67|
In today’s Modern Medicine series, CNBC’s Meg Tirrell brings us the story of a little girl whose life was saved by a different kind of cancer treatment.
Novartis raised eyebrows with the price of its newly approved CAR-T therapy: $475,000. But some argue the price makes sense, given that CAR-T is a one-time treatment, not a chronic therapy, and there are only about 600 patients each year who may take i...
Gilead Sciences’ $11 billion bet on Kite Pharma is poised to pay off, with the approval of Kite’s flagship cell-therapy treatment for advanced lymphoma patients.
U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc's Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer. The Food and Drug Administration approved the gene therapy, to be sold under the name Yescarta, to treat adults with large B-cell lymphoma, a type of non-Hodgkin lymphoma, who have failed to respond to other treatments.
The Food and Drug Administration just approved Yescarta, a treatment that genetically modifies a patient's own white cells to battle lymphoma. The price? $373,000.
Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.
Swiss drugmaker Novartis AG plans to reduce or drop production of some generic drugs and will close its 450-employee Sandoz plant in Broomfield over the next two years as a result. The Sandoz facility has been in Broomfield for 42 years. Novartis (NVS) plans to consolidate production of drug ingredients at a sister plant in Wilson, North Carolina, and shut down the Broomfield manufacturing plant by the end of 2019, the company said.
Gilead's new Kite Pharma unit is a leader in cutting-edge CAR-T therapy that fights cancer by rebuilding a patient's cells. Here's how its treatment stands out and who it helps.
Markets barely reacted when Gilead Sciences Inc. (NASDAQ:GILD) announced on Sept. 14 that it would buy Kite Pharma, Inc. for $11.9 billion. The slowdown in Gilead’s HCV business is starting to come to an end. The HCV segment will continue adding meaningfully to Gilead’s cash flow, which is money it needs to fund the Kite acquisition.
Novartis (NOVN.S) has decided not to sell its roughly $14 billion (10.61 billion pounds), 33 percent voting stake in Roche (ROG.S) following a review, Chairman Joerg Reinhardt said in an interview published on Wednesday in Swiss newspaper HandelsZeitung. "We said we would review whether it makes sense to sell the stake," Reinhardt told the newspaper. In May 2016, Chief Executive Officer Joe Jimenez said he was ready to sell the Roche stake without demanding a premium and that Novartis has been discussing options with banks.
Gene therapies like Spark Therapeutics' upcoming Luxturna and Novartis' FDA-approved Kymriah are raising concerns about the rising cost of health care, leading some experts to suggest new ways to price treatments based on the benefits they offer.
As of September 29, 2017, GlaxoSmithKline is trading at a forward PE (price-to-earnings) multiple of 14.2x, which is lower than the industry average of 15.7x.
Roche Holdings AG (RHHBY) announced that the FDA has accepted the company's sBLA and granted Priority Review for breast cancer drug regimen Perjeta
VANCOUVER , Oct. 3, 2017 /CNW/ - Trading resumes in: Company: Novicius Corp. CSE Symbol: NVS Resumption (ET): 9:30 am IIROC can make a decision to impose a temporary suspension (halt) of trading in a security ...
Credit Suisse Lilly’s Verzenio (abemaciclib) has obtained Food and Drug Administration approval for use in patients with HR+, HER2- metastatic breast cancer who progressed on prior therapy. Given the data that we have seen for Lilly’s (LLY) product from the MONARCH-1 and MONARCH-2 studies, we had expected the approval, although it does comes three to four months earlier than we had expected, representing another example of the agency working to get innovative products to the market quickly. Along with approval for use in combination with fulvestrant, Verzenio has the unique indication (relative to key competitors Pfizer’s (PFE) Ibrance and Novartis’s (NVS) Kisqali) for use as monotherapy after endocrine therapy and chemotherapy in patients with metastatic disease.
Kymriah is among a new wave of therapies that use a patient's own cells as medicine. But this historic treatment comes with a historic price.
Ligand's (LGND) Captisol formulation technology platform allows it to partner with several leading drug companies, thus helping it earn milestones and royalty payments in turn.
Health insurers and pharmacy benefits managers argue that drug prices should be tied to the benefits the products bring to patients, but the pharma industry has been slow to buy into that model.
Advanced Accelerator Applications launched to a record high Thursday on rumors Novartis could attempt to take it over.